Vnitr Lek 2020, 66(3):e55-e57

Proteinuria from an internist's point of view

Jan Vachek1,2, Adéla Maříková2, Kateřina Oulehle2, Oskar Zakiyanov3, Vladimír Tesař1
1 Klinika nefrologie 1. LF UK a VFN Praha
2 Interní oddělení a hemodialyzační středisko Klatovské nemocnice, a. s., Klatovy
3 Klinika nefrologie 1. LF UK a VFN v Praze

A basal level of proteinuria is about 30-100 mg/day, the upper limit of basal proteinuria does not exceed 150 mg/day which is considered non-pathology. Albumin accounts approximately 15 % of basal protein in the urine, other plasma proteins (immunoglobulins, β-2 microglobulin, Tamm-Horsfall mucoprotein) comprise the remaining 85 % of total quantity non-pathology proteinuria. Persistent proteinuria present for more than three months already meets the definition of chronic kidney disease independently of the stage of the estimated glomerular filtration rate. Patients are classified as A1-A3 based on the level of albuminuria. Examination of the albumin in the urine is one of the single sensitive indicators of chronic kidney disease. Proteinuria is an independent risk factor for cardiovascular disease, overall mortality and end stage renal failure both in general population and in population with chronic kidney disease. Presence of the urinary protein is associated with a higher mortality rate in critically ill patients. The degree of proteinuria after kidney transplantation predicts graft and patient survival in this population. Pharmacological and non-pharmacological treatments that attenuate proteinuria have been associated with better prognosis of kidney disease.

Keywords: proteinuria, albuminuria, creatinine, glomerulopathy, protein/creatinine ratio.

Published: May 26, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vachek J, Maříková A, Oulehle K, Zakiyanov O, Tesař V. Proteinuria from an internist's point of view. Vnitr Lek. 2020;66(3):e55-57.
Download citation

References

  1. Žabka J. Diferenciálnî diagnostika proteinurie. In: Viklický O, Dusilová-Sulková S, Rychlîk I Vyšetřovacî metody v nefrologii a jejich klinická aplikace. Praha: Tigis 2007, 17-22. Go to original source... Go to PubMed...
  2. Engliš M. Současné možnosti vyšetřovánî proteinuriî. In: Viklický O, Dusilová-Sulková S, Rychlîk I Vyšetřovacî metody v nefrologii a jejich klinická aplikace. Praha: Tigis 2007, 13-15.
  3. Thongboonkerd V, McLeish KR, Arthur JM et al. Proteomic analysis of human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 2002; 62: 1461-1469. Go to original source... Go to PubMed...
  4. Kouri T, Fogazzi G, Gant V et al. European Urinalysis Guidelines. Scand J Clin Lab Invest 2000; 60: (Suppl. 231): 1-96. Go to original source...
  5. Lamb EJ, MacKenzie F, Stevens PE. How should proteinuria be detected and measured? Ann Clin Biochem 2009; 46: 205-217. Go to original source... Go to PubMed...
  6. Rodby RA, Rohde RD, Sharon Z.et al. The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Am J Kidney Dis 1995; 26: 904-909. Go to original source... Go to PubMed...
  7. Russo LM, Comper WD, Osicka TM. Mechanism of albuminuria associated with cardiovascular disease and kidney disease. Kidney Int 2004; 66: (Suppl. 92): S67-S68. Go to original source... Go to PubMed...
  8. Levey AS et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 9: 17-28. Go to original source... Go to PubMed...
  9. https://www.england.nhs.uk/wp‑content/uploads/2014/06/psa‑risk‑preg‑wom.pdf (navštíveno 1. 9. 2018) Go to PubMed...
  10. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612. Go to original source... Go to PubMed...
  11. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003. Go to original source... Go to PubMed...
  12. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-1621. Go to original source... Go to PubMed...
  13. Mayer O, Cífková, Renata, Filipovský J, et al. Prevalence asymptomaticky vysokého rizika kardivaskulárních chorob ve vzorku obecné české populace a adherence k doporučeným cílovým hodnotám sekundární prevence. Prakt Lek 2010; 90: 5. Go to PubMed...
  14. Kotseva K, De Bacquer D, De Backer G, et al. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. Eur J Prev Cardiol 2016; 23: 2007-2018. Go to original source... Go to PubMed...
  15. Bruthans J, Cifkova R, Lanska V, et al. Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007. Eur J Prev Cardiol 2014; 21: 829-839. Go to original source... Go to PubMed...
  16. Nguyen TH, Neil CJ, Sverdlov AL et al. N‑terminal pro‑brain natriuretic protein levels in takotsubo cardiomyopathy. Am J Cardiol 2011; 108: 1316-1321. Go to original source... Go to PubMed...
  17. Lyon AL, Bossone E, Schneider B et al. Current state of knowledge on Takotsubo syndrome: a position statement from the task force on Takotsubo syndrome of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure 2016; 18: 8-27. Go to original source... Go to PubMed...
  18. Eitel I, Knobelsdorf‑Brenkenhoff F, Bernhardt P et al. Clinical Characteristics and Cardiovascular Magnetic Resonance Findings in Stress (Takotsubo) Cardiomyopathy. JAMA 2011; 306: 277-286. Go to original source... Go to PubMed...
  19. Babický M, Holm F, Erbrt M Takotsubo syndrom: incidencia, etiologie, komplikace, léčba a prognóza. Vnitř Lék 2016; 62: 1021-1027. Go to PubMed...
  20. Citro R, Rigo F, D'Andrea A et al. Echocardiographic correlates of acute heart failure, cardiogenic shock, and in‑hospital mortality in tako‑tsubo cardiomyopathy. JACC Cardiovasc Imaging 2014; 7: 119-129. Go to original source... Go to PubMed...
  21. Redfors B, Vedad R, Angerås O et al. Mortality in takotsubo syndrome is similar to mortality in myocardial infarction - A report from the SWEDEHEART1registry. Int J Cardiol 2015; 185: 282-289. Go to original source... Go to PubMed...
  22. Pelliccia F, Pasceri V, Patti G et al. Long‑term prognosis and outcome predictors in takotsubo syndrome: A systematic review and meta‑regression study. JACC Heart Fail 2019; 7: 143-154. Go to original source... Go to PubMed...
  23. Mehnert A, Lehmann C, Graefen M, et al. Depression, anxiety, post‑traumatic stress disorder and health‑related quality of life and its association with social support in ambulatory prostate cancer patients. Eur J Cancer Care (Engl) 2010; 19: 736-745. Go to original source... Go to PubMed...
  24. Thekdi SM, Milbury K, Spelman A, et al. Posttraumatic Stress and Depressive Symptoms in Renal Cell Carcinoma: Association with Quality of Life and Utility of Single Item Distress Screening. Psychooncology 2015; 24: 1477-1484. Go to original source... Go to PubMed...
  25. Geffen DB, Blaustein A. Post‑traumatic stress disorder and quality of life in long‑term survivors of Hodgkin's disease and non‑Hodgkin's lymphoma in Israel. Leuk Lymphoma 2003; 44: 1925-1929. Go to original source... Go to PubMed...
  26. Smith SK, Zimmerman S, Williams CS, et al. Post‑traumatic stress symptoms in long‑term non‑Hodgkin's lymphoma survivors: does time heal? J Clin Oncol 2011; 29: 4526-4533. Go to original source... Go to PubMed...
  27. Rodin G, Yuen D, Mischitelle A, et al. Traumatic stress in acute leukemia. Psychooncology 2013; 22: 299-307. Go to original source... Go to PubMed...
  28. Jawahri AR, Vandusen HB, Traeger LN, et al. Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation. Cancer 2016; 122: 806-812. Go to original source... Go to PubMed...
  29. Avery DH, Shah SH, Eder DN, et al. Nocturnal sweating and temperature in depression. Acta Psychiatr Scand 1999; 100: 295-301. Go to original source... Go to PubMed...
  30. Rietsema WJ. Post‑traumatic stress disorder as a cause of night sweats. Am Fam Physician 2003; 68: 806-808. Go to PubMed...
  31. Mold JW, Holtzclaw BJ, McCarthy L. Night sweats: a systematic review of the literature. J Am Board Fam Med 2012; 25: 878-893. Go to original source... Go to PubMed...
  32. Oka T. Psychogenic fever: how psychological stress affects body temperature in the clinical population. Temperature (Austin) 2015; 2: 368-378. Go to original source... Go to PubMed...
  33. Takakazu O. Psychogenic fever: how psychological stress affects body temperature in the clinical population. Temperature (Austin) 2015; 2: 368-378. Go to original source... Go to PubMed...
  34. Steen R, Dahl AA, Hess SL et al. A study of chronic fatigue in Norwegian cervical cancer survivors. Gynecol Oncol 2017; 146: 630-635. Go to original source... Go to PubMed...
  35. Nebiker L, Lichtenstein E, Minghetti A, et al. Moderating Effects of Exercise Duration and Intensity in Neuromuscular vs. Endurance Exercise Interventions for the Treatment of Depression: A Meta‑Analytical Review. Front Psychiatry 2018; 9: 305. Go to original source... Go to PubMed...
  36. Rebar RA, Stanton R, Geard D, et al. A meta‑analysis of the effect of physical activity on depression and anxiety in non‑clinical adult populations. Health Psychology Review 2015; 9: 366-378. Go to original source... Go to PubMed...
  37. Werneck AO, Oyeyemi AL, Silva Dr. Physical activity and depression: is 150 min/week of moderate to vigorous physical activity a necessary threshold for decreasing risk of depression in adults? Different views from the same data. Soc Psychiatry Psychiatr Epidemiol 2018; 53: 323-324. Go to original source... Go to PubMed...
  38. Marker RJ, Cox‑Martin E, Jankowski CM, et al. Evaluation of the effects of a clinically implemented exercise program on physical fitness, fatigue, and depression in cancer survivors. Support Care Cancer 2018; 26: 1861-1869. Go to original source... Go to PubMed...
  39. Hadrabová M, Janíková A. Význam fyzické aktivity pro přežití a kvalitu života u pacientů s lymfoproliferativním onemocněním. Transfuze a Hematologie dnes 2018; 3: 182-193.
  40. Janíková A, Radvanský J, Vysoký R, et al. Význam fyzické aktivity u pacientů s hematoonkologickými malignitami. Transfuze a hematologie dnes 2012; 18: 31-38.
  41. Cuisset L, Jeru I, Dumont B, et al. Mutation in the autoinflammatory cryopyrin‑associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis 2011; 70: 495. Go to original source... Go to PubMed...
  42. Toplak N, Doležalová P, Constantin T, et al. Periodic Fever syndromes in Eastern and Central European countries: result of a pediatric multinational survey. Pediatric Rheumatology 2010; 8: 29. Go to original source... Go to PubMed...
  43. Toplak N, Frenkel J, Ozen S, et al. An international registry on autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis 2012; 71: 1177-1182. Go to original source... Go to PubMed...
  44. Shinar, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis 2012; 71: 1599-1605. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.